Mahady, Redmond move up at Wyeth

Share this article:
Wyeth named Joe Mahady president, Wyeth Pharmaceuticals and SVP, Wyeth.

In February, Mahady was named president, global business for the company's pharmaceuticals division, with responsibility for all worldwide commercial business. Prior to that, he was president, Americas and global business, in which role he presided over steep cuts in the company's US primary care sales force, supplemented by the hiring of flex-time reps. He joined the company in 1979 as a pharmacist with its regulatory affairs division.

Also moving up are Wyeth BioPharma head Cavan Redmond, who becomes president, Wyeth Consumer Healthcare, and Richard DeLuca, who becomes president, Fort Dodge Animal Health.

They will assume their new roles Jan. 1, the day Bernard Poussot takes the reins from CEO Bob Essner, who is retiring.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.